Amarin (NASDAQ:AMRN - Get Free Report) is scheduled to be issuing its quarterly earnings data after the market closes on Wednesday, October 30th. Analysts expect the company to announce earnings of ($0.05) per share for the quarter. Parties that wish to listen to the company's conference call can do so using this link.
Amarin Stock Down 2.1 %
AMRN stock traded down $0.01 during trading on Wednesday, hitting $0.57. The company had a trading volume of 190,481 shares, compared to its average volume of 1,552,263. The firm has a market capitalization of $232.44 million, a P/E ratio of -4.82 and a beta of 1.92. Amarin has a 52-week low of $0.57 and a 52-week high of $1.37. The company has a 50 day simple moving average of $0.60 and a 200-day simple moving average of $0.73.
Insider Buying and Selling
In related news, CEO Aaron Berg purchased 160,000 shares of Amarin stock in a transaction that occurred on Friday, August 2nd. The shares were bought at an average price of $0.64 per share, with a total value of $102,400.00. Following the purchase, the chief executive officer now directly owns 805,380 shares of the company's stock, valued at approximately $515,443.20. This represents a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.96% of the stock is currently owned by insiders.
Analysts Set New Price Targets
Separately, StockNews.com downgraded shares of Amarin from a "buy" rating to a "hold" rating in a research note on Thursday, July 4th.
Get Our Latest Stock Report on Amarin
About Amarin
(
Get Free Report)
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
See Also
Before you consider Amarin, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amarin wasn't on the list.
While Amarin currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
